LeaderMed Group And OPKO Form Joint Venture To Develop And Commercialize Oxyntomodulin And Factor VIIa-CTP In China And Other Asian Territories; Opko To Grant JV Rights To OPK88003 And Factor VIIa-CTP For 47% JV Interest And $1M Upfront Payment